Tag: amarin
December 13, 2018
Pharma Trends 2018: Drug Pricing Takes Center Stage
Knowing what pharma trends influenced the market this year may be key for new and ongoing investing opportunities. August 27, 2018
Amarin’s REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results
Amarin (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today commented that following... April 12, 2018
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin-Treated Patients with Reduced Kidney Function and Persistent High Triglycerides
Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced the... April 4, 2018
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today... February 27, 2018
Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations
Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial... January 30, 2018
Amarin Announces Proposed Public Offering of American Depositary Shares
Amarin (NASDAQ:AMRN) today announced a registered underwritten public offering of its American Depositary Shares. All of the shares in the proposed... January 18, 2018